Cargando…
Cell Therapy in Idiopathic Pulmonary Fibrosis†
Idiopathic pulmonary fibrosis is a fatal disease with no effective or curative treatment options. In recent decades, cell-based therapies using stem cells or lung progenitor cells to regenerate lung tissue have experienced rapid growth in both preclinical animal models and translational clinical stu...
Autor principal: | |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2018
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6164035/ https://www.ncbi.nlm.nih.gov/pubmed/30104544 http://dx.doi.org/10.3390/medsci6030064 |
_version_ | 1783359504204693504 |
---|---|
author | Serrano-Mollar, Anna |
author_facet | Serrano-Mollar, Anna |
author_sort | Serrano-Mollar, Anna |
collection | PubMed |
description | Idiopathic pulmonary fibrosis is a fatal disease with no effective or curative treatment options. In recent decades, cell-based therapies using stem cells or lung progenitor cells to regenerate lung tissue have experienced rapid growth in both preclinical animal models and translational clinical studies. In this review, the current knowledge of these cell therapies is summarized. Although further investigations are required, these studies indicate that cell therapies are a promising therapeutic approach for the treatment of idiopathic pulmonary fibrosis. |
format | Online Article Text |
id | pubmed-6164035 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2018 |
publisher | MDPI |
record_format | MEDLINE/PubMed |
spelling | pubmed-61640352018-10-10 Cell Therapy in Idiopathic Pulmonary Fibrosis† Serrano-Mollar, Anna Med Sci (Basel) Review Idiopathic pulmonary fibrosis is a fatal disease with no effective or curative treatment options. In recent decades, cell-based therapies using stem cells or lung progenitor cells to regenerate lung tissue have experienced rapid growth in both preclinical animal models and translational clinical studies. In this review, the current knowledge of these cell therapies is summarized. Although further investigations are required, these studies indicate that cell therapies are a promising therapeutic approach for the treatment of idiopathic pulmonary fibrosis. MDPI 2018-08-13 /pmc/articles/PMC6164035/ /pubmed/30104544 http://dx.doi.org/10.3390/medsci6030064 Text en © 2018 by the author. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/). |
spellingShingle | Review Serrano-Mollar, Anna Cell Therapy in Idiopathic Pulmonary Fibrosis† |
title | Cell Therapy in Idiopathic Pulmonary Fibrosis† |
title_full | Cell Therapy in Idiopathic Pulmonary Fibrosis† |
title_fullStr | Cell Therapy in Idiopathic Pulmonary Fibrosis† |
title_full_unstemmed | Cell Therapy in Idiopathic Pulmonary Fibrosis† |
title_short | Cell Therapy in Idiopathic Pulmonary Fibrosis† |
title_sort | cell therapy in idiopathic pulmonary fibrosis† |
topic | Review |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6164035/ https://www.ncbi.nlm.nih.gov/pubmed/30104544 http://dx.doi.org/10.3390/medsci6030064 |
work_keys_str_mv | AT serranomollaranna celltherapyinidiopathicpulmonaryfibrosis |